michigan semaglutide pancreatitis attorney glp-1 legal team in A Comprehensive Review of the Role of GLP-1 S-1/A

Injected semaglutide is well-studied and known for its strong effectiveness

Starting July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) will launch a new federal program that gives many Medicare beneficiaries access to GLP-1 medications for weight management for the first time

n = 56) led to a mean BMI reduction of 5.8% at week 56, while those receiving placebo (n = 26) saw a 1.6% increasea difference of 7.4 percentage points (95% CI: 11.6 to 3.2

Those users appear in surveys but not in claims datasets

In both cases, effectiveness also hinges on the care plan around the medicine, including dosing tempo, nutrition targets, and follow up